Justin Stebbing MA FRCP FRCPath PhD, 2-sided Curriculum vitae

PERSONAL DETAILS

NameJustin STEBBING (mobile 07802264097)

Date of birth21st January, 1971

NationalityBritish, 2 children

NHS Work AddressImperial College Healthcare NHS Trust, The Hammersmith Hospitals, Charing Cross site, First Floor, East Wing, Fulham Palace Road, London, W6 8RF, UK, Hammersmith Site, ICTEM, Du Cane Road, W12 0NN, UK

Current PositionProfessor of Cancer Medicine and Medical Oncology, Imperial College, London. 2012 awarded The 1st NIHR Translational Research Professorship (by Dame Sally Davies, the UK’s Chief Medical Officer).

E or

Academic PAMaureen Francis, l: 0207594279

NHS PAPenny Johnson, Tel: 02033118295

Private PALesley Bedford, Tel: 02073172573

Previously, senior lecturer in medical oncology at Imperial (2006 – 2010); specialist Registrar in Medical Oncology atBarts and the London NHS Trust(2004 – 2006) and The Royal Marsden NHS Trust (1999 – 2001); Medical Research Council Clinical Training Fellow, ImperialCollege London (2001 – 2003). Medical student at Trinity College Oxford (1989 – 1995, first class degree) followed by a residency at The Johns Hopkins Hospital, Baltimore, USA (1996 – 1999).
Editorial boards include Journal of Clinical Oncology, The Lancet Oncology and Oncogene (Springer Nature’s leading cancer journal), for which I am Editor-in-Chief. Other positions include Chair of the Irish Cancer Society oversight committee, Board of Directors Curemark, Chair of Scientific Advisory Boards Heat Biologics, Proton Partners, APIM Therapeutics, Imagen Biotech. In 2016 I was elected to be a Fellow of the American Society for Clinical Investigation.
Founded Action Against Cancer, ; this has raised a substantial amount to support my research.

EDUCATION AND QUALIFICATIONS

2016Elected to American Society for Clinical Investigation,

2007FRCPath

2006FACP

2003PhD

1998MRCP

1995BM BCh MA (Oxon.)

University 1989-1995:Oxford University School of Medicine, Trinity College.

1992Degree result: First class (BA in Physiological Sciences).

Tumour types: Breast, all gastro-intestinal, lung, melanoma and rare cancers/cancer of unknown primary; numerous MDTs chaired.30 recent publications have been selected from the last year only emphasising broad remit of bench to bedside, and back to bench, research (submitted/in press papers not included):

2017:

  1. Craddock C, Cathcart P,Stebbing J. Chilli – too hot to handle?The Lancet Oncology, 2017;17:30522.
  2. Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Goddard KS, Hastings RK, Luo J, Ogle O, Woodley L, Ali S, Stebbing J, Coombes RC. Mutation analysis of cell free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts. Clinical Cancer Research, 2017;23:88-96.
  3. Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJCT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.The Lancet Oncology, 2017; pii: S1470-2045(17)30434-5.
  4. Cathcart P, Craddock C, Stebbing J. Fasting: starving cancer. The Lancet Oncology, 2017;18:431.
  5. Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N. Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.Cell Reports, 2017;18:1687-1698.
  6. Askari A, Nachiappan S, Currie A, Latchford A, Stebbing J, Athanasiou T, Faiz O. The relationship between ethnicity, social deprivation and late presentation of colorectal cancer. Cancer Epidemiology, 2017;47:88-93.
  7. Castellano L, Dabrowska A, Pellegrino L, Ottaviani S, Cathcart P, Frampton AE, Krell J, Stebbing J. Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.Nucleic Acids Research, 2017;45:4401-4412.
  8. Page K, Guttery DS, Fernandez-Garcia D, Hills A, Goddard K, Shahin V, Woodley- Rosales BM, Coombes RC, Stebbing J, Shaw JA. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.Clinical Chemistry, 2017;63:532-541.
  9. Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, Metodieva G, de Giorgio A, Williams RL, Santos DB, Gomez PJ, Lin ML, Metodiev MV, Stebbing J, Castellano L, Magnani L, Coombes RC, Buluwela L, Ali S. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.Oncogene, 2017;36:2286-2296.
  10. Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.Journal of Hepatology, 2017;66:338-346.
  11. Chandrasinghe P, Stebbing J, Warusavitarne J. The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer.Oncogene, 2017;36:1474-1478.

2016:

  1. Balachandran K, Stebbing J. Tumeric: a spice for life.The Lancet Oncology, 2016;17:1639.
  2. Tree AC, Harding V, Bhangu A, Krishnasamy V, Morton D, Stebbing J, Wood BJ, Sharma RA. The need for multidisciplinarity in specialist training to optimize future patient care.Nature Reviews Clinical Practice Oncology, 2016, Epub ahead of print.
  3. *KrellJ*, Stebbing J*, Carissimi C, Dabrowska AF, de Giorgio A, Frampton A , Harding V, Fulci V, Macino G, Colombo T, Castellano L. p53 regulates miRNA loading onto AGO2 and remodels the miRNA-mRNA interaction network. Genome Research, 2016;26:331-341. *joint first author.
  4. Pardo O, Munro CE, Castellano L, Hu Y, Mauri F, Frampton AE, Krell J, Pinho FG, Pellegrino L, Pshezhetsky D, Wang Y, Waxman J, Seckl MJ, Stebbing J. miR-515-5p controls cancer cell migration through MARK4 regulation. EMBO Reports, 2016;17:570-584.
  5. Jacob J, Favicchio R, Karimian N, Mehrami M, Harding V, Castellano L, Stebbing J, Giamas G. LMTK3 escapes tumor suppressive microRNAs via sequestration of DDX5. Cancer Letters, 2016;372:137-146.
  6. Miller HC, Frampton AE, Castellano L, Hanna GB, Stebbing J, Frilling A. MicroRNAs associated with small bowel neuroendocrine tumors and their metastases. Endocrine Related Cancer, 2016;23:711-726.
  7. di Giorgio A, Stebbing J. Aloe vera: a natural cancer soother. Lancet Oncology, 2016;17:421-423.
  8. Coombes RC, Kilburn LS, Perez-Lopez FR, Palmieri C, Stebbing J, Bliss JM. Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.European Journal of Cancer, 2016;60:146-153.
  9. Frampton AE, Krell J, Mato Prado M, Gall TM, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, Giovannetti E, Castellano L, Basyouny M, Habib NA, Kaltsidis H, Vlavianos P, Stebbing J, Jiao LR. Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies.Oncotarget, 2016;7:28556-28569.
  10. Angelopoulos N, Stebbing J, Xu Y, Giamas G, Zhang H. Proteome-wide analysis of functional datasets in breast cancer. Data Brief, 2016;7:740-746.
  11. Nunes J, Zhang H, Angelopoulos N, Chhetri J, Osipo C, Grothey A, Stebbing J, Giamas G. ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation.Oncotarget, 2016;7:27599-27612.
  12. Neofytou K, Giakoustidis A, Neves MC, Morrison D, Khan AZ, Stebbing J, Mudan S. Increased carcinoembryonic antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases.Archives of Surgery, 2016;402:599-605.
  13. Brown M, Black JR, Sharma R, Stebbing J, Pinato DJ. Gene of the month: Axl. Journal of Clinical Pathology, 2016;69:391-397.
  14. Pinato DJ, Stebbing J. Melatonin: resetting the clock of cancer progression. Lancet Oncology, 2016;17:23-24.
  15. di Giorgio A, Stebbing J. Garlic: a stake through the heart of cancer. Lancet Oncology, 2016;17:879-880.
  16. Mato Prado M, Frampton AE, Stebbing J, Krell J. Single cell sequencing in cancer research. Expert Reviews in Molecular Diagnostics, 2016;16:1-5.
  17. Favicchio R, Thepaut C, Zhang H, Arends R, Stebbing J, Giamas G. Strategies in functional proteomics: unveiling pathways in precision oncology. Cancer Letters, 2016;382:86-94.
  18. Rampias T, Favicchio R, Stebbing J, Giamas G. Targeting tumor-stroma cross-talk: the example of the NT157 inhibitor. Oncogene, 2016;35:2562-2568.
  19. Pinato DJ, Chowdhury S, Stebbing J. TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene, 2016;34:2684-2686.

References upon request (Professors Waxman and Lalvani: and ).

1